UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(Commission File Number)
|
(State or other jurisdiction of incorporation) |
(I.R.S. Employer Identification No.) |
|
|
| |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 3, 2025, Fennec Pharmaceuticals Inc. (the “Company”) held an annual meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:
1. The following five (6) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:
| Name of Nominee | Votes For | Votes Withheld | Broker Non-Votes |
| Dr. Khalid Islam | 13,432,561 | 304,760 | 5,580,283 |
| Chris A. Rallis | 13,808,792 | 354,099 | 5,580,283 |
| Marco Brughera | 13,807,501 | 355,390 | 5,580,283 |
| Jodi Cook | 13,259,894 | 902,997 | 5,580,283 |
| Rostislav Raykov | 13,432,561 | 730,330 | 5,580,283 |
| Jeffrey Hackman | 13,495,309 | 687,582 | 5,580,283 |
2. The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:
| Votes For | 19,673,487 |
| Votes Withheld | 69,405 |
| Votes Against | 282 |
| Broker Non-Votes | 0 |
3. The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:
| Votes For | 12,110,598 |
| Votes Against | 1,595,423 |
| Abstentions | 456,870 |
| Broker Non-Votes | 5,580,283 |
4. The resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan was approved based on the following vote:
| Votes For | 12,927,131 |
| Votes Against | 776,907 |
| Abstentions | 458,853 |
| Broker Non-Votes | 5,580,283 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| FENNEC PHARMACEUTICALS INC. | ||
| Date June 3, 2025 | By: | /s/ Robert Andrade |
|
Robert Andrade Chief Financial Officer |
3